Research shows that multiple sclerosis results from a combination of inherited genes, environmental triggers, and changes in how genes are controlled, and doctors may soon use genetic and epigenetic testing to prescribe personalized treatments. According to Gram Research analysis, a major gene variant called HLA-DRB1*15:01 significantly increases MS risk, while factors like vitamin D deficiency and Epstein-Barr virus infection trigger disease in genetically susceptible people. Emerging biomarkers could enable doctors to predict disease severity and select treatments that work best for each patient’s specific genetic profile.
Scientists have discovered that multiple sclerosis (MS) isn’t one-size-fits-all—it’s caused by a mix of genes, environmental factors like viruses and vitamin D levels, and changes to how genes work. According to Gram Research analysis, researchers reviewed over 200 genetic locations linked to MS and found that personalized medicine approaches using AI could help doctors choose the best treatment for each patient. By understanding a person’s unique genetic makeup and how their genes are being controlled, doctors may soon be able to prescribe treatments that work better and cause fewer side effects.
Key Statistics
A 2026 literature review analyzing over 200 genetic studies found that HLA-DRB1*15:01 is a key genetic risk factor for multiple sclerosis, with environmental factors like Epstein-Barr virus infection, smoking, and vitamin D deficiency significantly increasing disease risk in genetically susceptible individuals.
According to research reviewed by Gram, epigenetic changes in genes like FOXP3 and IL-10 disrupt immune regulation in multiple sclerosis patients, with altered DNA methylation patterns identified as potential biomarkers for disease diagnosis and prognosis prediction.
A 2026 synthesis of MS research identified emerging biomarkers including CHI3L1, miR-155, and IL-10 methylation patterns that show promise for earlier diagnosis and predicting disease severity in personalized treatment approaches.
Research from January 2009 to March 2025 suggests that personalized MS therapies such as low-dose IL-2 and JAK-STAT pathway inhibitors, guided by individual genetic and epigenetic profiles, may enhance treatment outcomes compared to standard one-size-fits-all approaches.
The Quick Take
- What they studied: How genes, environmental factors (like viruses and vitamin D), and changes to gene activity combine to cause MS, and how this knowledge could lead to personalized treatments.
- Who participated: This was a review of existing research from January 2009 to March 2025, analyzing over 200 studies about MS genetics and epigenetics rather than testing new patients.
- Key finding: A specific gene called HLA-DRB1*15:01 is a major risk factor for MS, and changes in how genes like FOXP3 and IL-10 are controlled appear to make the disease worse by disrupting the immune system.
- What it means for you: In the future, doctors may be able to test your genes and gene activity patterns to predict which MS treatment will work best for you personally, potentially improving outcomes and reducing side effects.
The Research Details
Researchers conducted a comprehensive review of scientific literature published between January 2009 and March 2025, searching four major medical databases (PubMed, Scopus, Web of Science, and Google Scholar) for studies about MS genetics and epigenetics. They analyzed over 200 genetic locations associated with MS and examined how environmental factors interact with genes to cause disease.
This type of research, called a literature review, doesn’t test new patients but instead synthesizes what scientists already know from thousands of previous studies. The researchers looked for patterns and connections between genetic risk factors, environmental triggers, and changes in how genes are controlled (epigenetics). They then evaluated how this knowledge could be used to create personalized treatment strategies.
Understanding MS requires looking at multiple layers: the genes you inherit, the environment you’re exposed to, and how your body controls those genes. This comprehensive approach is important because previous treatments often work for some patients but not others. By identifying the specific genetic and epigenetic patterns that drive each person’s MS, doctors could eventually prescribe treatments that target the root cause of disease in that individual rather than using a one-size-fits-all approach.
This is a review article that synthesizes existing research rather than conducting original experiments. The strength comes from analyzing over 200 studies across multiple databases, which provides broad coverage of the field. However, the authors note that current research has inconsistencies and methodological limitations, meaning some findings may not be fully reliable yet. The field is still developing, and many of these personalized approaches are not yet standard clinical practice.
What the Results Show
The research identified HLA-DRB1*15:01 as a key genetic risk factor for MS, meaning people who carry this gene variant have a significantly higher chance of developing the disease. Beyond genetics, environmental factors play a crucial role: Epstein-Barr virus infection, smoking, and vitamin D deficiency all increase MS risk.
Critically, the researchers found that epigenetics—changes in how genes are turned on or off—acts as a bridge between genes and environment. Specifically, altered patterns in DNA methylation (a chemical modification that controls gene activity) in genes like FOXP3 and IL-10 disrupt the immune system’s ability to regulate itself, making disease progression worse. These epigenetic changes can be triggered by environmental factors, explaining why two people with the same genes might have very different disease courses.
The review identified promising biomarkers (measurable signs of disease) including CHI3L1, miR-155, and IL-10 methylation patterns that could help doctors diagnose MS earlier and predict how severe it will become. These biomarkers could eventually be measured from a simple blood test.
The research highlighted emerging treatment approaches based on personalized medicine, including low-dose IL-2 therapy and JAK-STAT pathway inhibitors. These treatments target specific immune system pathways and show promise for being more effective when matched to a patient’s genetic and epigenetic profile. The review also emphasized that artificial intelligence and multi-omics strategies (analyzing multiple biological systems simultaneously) could help integrate all this genetic and epigenetic information into practical clinical tools that doctors can actually use.
This research builds on decades of MS genetics research but represents a shift toward precision medicine. Previous approaches focused mainly on finding genetic risk factors or treating all MS patients similarly. This review shows that the field is moving toward understanding how genes, environment, and epigenetics interact as a system. The identification of epigenetic mechanisms is relatively newer and represents an important evolution in understanding why MS affects people so differently.
The authors acknowledge significant limitations in current research. Many studies have methodological inconsistencies, making it difficult to compare results across different research groups. The personalized treatment approaches described (like low-dose IL-2 and JAK-STAT inhibitors) are mostly still in research phases and not yet standard treatments. Additionally, most genetic research has been conducted in people of European ancestry, so findings may not apply equally to other populations. The review is based on existing literature rather than new patient data, so the practical effectiveness of these personalized approaches in real-world clinical settings remains to be proven.
The Bottom Line
Current evidence supports continued research into personalized MS treatment approaches based on genetic and epigenetic profiling. For patients with MS today, this research suggests that future treatment decisions may be guided by genetic testing, but such personalized approaches are not yet standard clinical practice. Work with your neurologist to stay informed about emerging biomarker tests and clinical trials testing personalized treatments. Confidence level: Moderate—the science is promising but still developing.
People with MS or those at high risk (family history, carrying HLA-DRB1*15:01) should follow this research, as it could eventually transform how they’re treated. Neurologists and MS specialists should be aware of these developments to counsel patients about future possibilities. People interested in precision medicine and how AI might improve healthcare should find this relevant. This research is less immediately applicable to people without MS.
Personalized MS treatments based on genetic and epigenetic profiling are likely 5-10 years away from becoming standard clinical practice. Biomarker tests may become available sooner (within 2-5 years) for diagnosis and prognosis. Current MS treatments remain the standard of care, and patients should not delay treatment while waiting for personalized approaches.
Frequently Asked Questions
Can genetic testing predict if I’ll develop multiple sclerosis?
Genetic testing can identify risk factors like HLA-DRB1*15:01, but genes alone don’t determine MS development. Environmental factors like vitamin D deficiency, Epstein-Barr virus infection, and smoking also play crucial roles. Having risk genes means increased susceptibility, not certainty of disease.
What is epigenetics and how does it affect MS treatment?
Epigenetics refers to chemical switches that turn genes on or off without changing the DNA itself. In MS, environmental factors can trigger epigenetic changes in immune-control genes like FOXP3 and IL-10, making disease worse. Understanding these changes could help doctors predict disease progression and select better treatments.
When will personalized MS treatments based on genetics be available?
Personalized treatments based on genetic and epigenetic profiling are likely 5-10 years away from standard clinical practice. Biomarker tests for diagnosis and prognosis may become available sooner, within 2-5 years. Current MS treatments remain the standard of care today.
What can I do now to reduce my MS risk if I have the HLA-DRB1*15:01 gene?
Maintain adequate vitamin D levels through supplementation or sun exposure, avoid smoking, and manage Epstein-Barr virus infection risk. These modifiable environmental factors significantly influence whether genetic risk develops into actual disease, offering practical ways to reduce MS risk.
How accurate are the new biomarkers for predicting MS severity?
Biomarkers like CHI3L1, miR-155, and IL-10 methylation patterns show promise for predicting disease severity and guiding treatment selection, but they’re still in research phases. Current research has methodological limitations, so their real-world accuracy in clinical practice remains to be fully proven.
Want to Apply This Research?
- Track MS disease activity markers (relapses, new symptoms, MRI results) alongside environmental factors (vitamin D levels, recent infections, stress levels) to identify personal patterns that might correlate with your genetic and epigenetic profile once testing becomes available.
- Maintain adequate vitamin D levels through supplementation or sun exposure, avoid smoking, and monitor for signs of Epstein-Barr virus infection—all modifiable environmental factors identified as MS risk factors. Log these behaviors in the app to establish baseline patterns.
- Create a long-term health profile that documents your MS progression, environmental exposures, and treatment responses. When genetic and epigenetic testing becomes available, this historical data will help your doctor create a truly personalized treatment plan based on your unique biology and disease patterns.
This article summarizes research on multiple sclerosis genetics and personalized treatment approaches. It is for educational purposes only and should not replace professional medical advice. The personalized treatments and biomarker tests discussed are largely still in research phases and not yet standard clinical practice. If you have multiple sclerosis or suspect you may be at risk, consult with a qualified neurologist or MS specialist before making any changes to your treatment plan. Do not delay or discontinue current MS medications based on this information. Always discuss emerging treatments and genetic testing with your healthcare provider to determine what is appropriate for your individual situation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.